Top

Cardiovascular Drugs and Therapy

Published in:

01-08-2009

Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension

Author: Alan S. Maisel

Published in: Cardiovascular Drugs and Therapy | Issue 4/2009

Abstract

Introduction

Surrogate markers represent a significant contribution to early diagnosis, longitudinal prognoses, and outcome prediction in cases of hypertension. They often enable detection of disease and disease potential when the disease is still subclinical and are useful noninvasive tools for designing and evaluating therapeutic programs. Surrogate markers are increasingly employed as predictive endpoints for treatment.

Methods

Key studies supporting the importance of surrogate markers as diagnostic and prognostic predictors of cardiovascular and renal clinical outcomes in hypertension, as well as what is known about the effects of renin-angiotensin-aldosterone system-blocking agents on these biomarkers were reviewed.

Results

Clinical data supporting the use of surrogate markers for heart failure, such as brain natriuretic peptide (BNP) and N-terminal prohormone BNP; markers for renal function, such as urinary albumin to creatinine ratio (UACR), urinary albumin excretion rates (UAER), and creatinine, reflecting glomerular filtration; and markers of cardiac remodeling, such as left ventricular hypertrophy and calculations of left ventricular mass index (LVMI), were reviewed for their utility in improving prognosis and treatment efficacy. Finally, hypertension treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and potentially direct renin inhibitors can significantly improve outcomes predicted by surrogate markers.

Conclusions

BNP, UACR, UAER, and LVMI, among others, have been increasingly established as valid surrogate markers with significant value for hypertension prognosis and therapy. The benefits of using surrogate markers to gauge the effectiveness of hypertension therapy in reducing renal and cardiac complications can be seen in improved morbidity and mortality.

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95. doi:10.1067/mcp.2001.113989.

Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J. 2006;8:E146–52. doi:10.1208/aapsj080117.PubMedCrossRef

Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999;282:790–5. doi:10.1001/jama.282.8.790.PubMedCrossRef

Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med. 1994;13:955–68. doi:10.1002/sim.4780130906.PubMedCrossRef

Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989;8:431–40. doi:10.1002/sim.4780080407.PubMedCrossRef

Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605–13.PubMed

Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949–52. doi:10.1161/CIRCULATIONAHA.106.683110.PubMedCrossRef

Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52. doi:10.1161/01.HYP.0000107251.49515.c2.PubMedCrossRef

Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–26. doi:10.1161/CIRCULATIONAHA.108.189141.PubMedCrossRef

10.

Knaapen P, Germans T, Camici PG, et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;294:H986–93. doi:10.1152/ajpheart.00233.2007.PubMedCrossRef

11.

Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–52.PubMed

12.

Tune JD. Control of coronary blood flow during hypoxemia. Adv Exp Med Biol. 2007;618:25–39. doi:10.1007/978-0-387-75434-5_3.PubMedCrossRef

13.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13. doi:10.1016/S0140-6736(02)11911-8.PubMedCrossRef

14.

Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. Lancet. 1990;336:370–1. doi:10.1016/0140-6736(90)91908-S.PubMedCrossRef

15.

Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–38. doi:10.1016/0140-6736(90)90944-Z.PubMedCrossRef

16.

MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–74. doi:10.1016/0140-6736(90)90878-9.PubMedCrossRef

17.

Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117. doi:10.1186/1471-2458-8-117.PubMedCrossRef

18.

Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.PubMed

19.

McCullough PA, Li S, Jurkovitz CT, et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51:S38–45. doi:10.1053/j.ajkd.2007.12.017.PubMedCrossRef

20.

Barri YM. Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep. 2008;10:39–45. doi:10.1007/s11906-008-0009-y.PubMedCrossRef

21.

Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–61.PubMed

22.

Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–16. doi:10.1056/NEJMoa0707064.PubMedCrossRef

23.

Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:9–20.PubMed

24.

Piepho RW, Beal J. An overview of antihypertensive therapy in the 20th century. J Clin Pharmacol. 2000;40:967–77. doi:10.1177/00912700022009693.PubMedCrossRef

25.

Bhatia V, Nayyar P, Dhindsa S. Brain natriuretic peptide in diagnosis and treatment of heart failure. J Postgrad Med. 2003;49:182–5.PubMed

26.

Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92:843–9. doi:10.1136/hrt.2005.071233.PubMedCrossRef

27.

Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8. doi:10.1056/NEJM199807303390507.PubMedCrossRef

28.

McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416–22. doi:10.1161/01.CIR.0000025242.79963.4C.PubMedCrossRef

29.

Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–54. doi:10.1016/j.amjcard.2004.12.032.PubMedCrossRef

30.

Latini R, Masson S, Wong M, et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;119:e23–30.PubMedCrossRef

31.

Balion CM, Santaguida P, McKelvie R, et al. Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. Clin Biochem. 2008;41:231–9. doi:10.1016/j.clinbiochem.2007.10.005.PubMedCrossRef

32.

Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007;9:787–94. doi:10.1016/j.ejheart.2007.04.001.PubMedCrossRef

33.

Luchner A, Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005;46:118–23. doi:10.1161/01.HYP.0000170140.36633.8f.PubMedCrossRef

34.

Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res. 2002;25:669–76. doi:10.1291/hypres.25.669.PubMedCrossRef

35.

Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005;46:660–6. doi:10.1161/01.HYP.0000179575.13739.72.PubMedCrossRef

36.

Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension—a marker for left ventricular dimensions and prognosis. Eur J Heart Fail. 2004;6:313–7. doi:10.1016/j.ejheart.2004.01.001.PubMedCrossRef

37.

Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003. doi:10.1016/S0140-6736(02)08089-3.PubMedCrossRef

38.

Olsen MH, Wachtell K, Nielsen OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens. 2006;24:1531–9. doi:10.1097/01.hjh.0000239288.10013.04.PubMed

39.

Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75. doi:10.1056/NEJMoa010713.PubMedCrossRef

40.

Westermann D, Schmieder R, Schultheiss HP, Tschope C. Renin inhibitors, clinical experience. J Mol Med. 2008;86:691–5. doi:10.1007/s00109-008-0338-y.PubMedCrossRef

41.

McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17–24.CrossRefPubMed

42.

Recio-Mayoral A, Kaski JC, McMurray JJ, et al. Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. Cardiovasc Drugs Ther. 2007;21:459–65. doi:10.1007/s10557-007-6069-4.PubMedCrossRef

43.

Devereux RB. Therapeutic options in minimizing left ventricular hypertrophy. Am Heart J. 2000;139:S9–14. doi:10.1067/mhj.2000.102902.PubMedCrossRef

44.

Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580–6.PubMed

45.

Hammond IW, Devereux RB, Alderman MH, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol. 1986;7:639–50.PubMedCrossRef

46.

Liebson PR, Grandits G, Prineas R, et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993;87:476–86.PubMed

47.

Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684–90. doi:10.1161/01.CIR.0000083724.28630.C3.PubMedCrossRef

48.

Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol. 1998;31:383–90. doi:10.1016/S0735-1097(97)00493-2.PubMedCrossRef

49.

Casiglia E, Schiavon L, Tikhonoff V, et al. Electrocardiographic criteria of left ventricular hypertrophy in general population. Eur J Epidemiol. 2008;23:261–71. doi:10.1007/s10654-008-9234-6.PubMedCrossRef

50.

Gardin JM, McClelland R, Kitzman D, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol. 2001;87:1051–7. doi:10.1016/S0002-9149(01)01460-6.PubMedCrossRef

51.

Levy D. Clinical significance of left ventricular hypertrophy: insights from the Framingham Study. J Cardiovasc Pharmacol. 1991;17:S1–6. doi:10.1097/00005344-199117002-00002.PubMedCrossRef

52.

Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786–93.PubMed

53.

de Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J. 2008;29:741–7. doi:10.1093/eurheartj/ehm605.PubMedCrossRef

54.

Rosenberg M, Zugck C, Nelles M, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008;1:43–9.CrossRefPubMed

55.

Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol. 2005;20:201–10. doi:10.1097/01.hco.0000161832.04952.6a.PubMedCrossRef

56.

Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500–8. doi:10.1038/ajh.2008.16.PubMedCrossRef

57.

Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18:1465–75. doi:10.1097/00004872-200018100-00015.PubMedCrossRef

58.

Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001;104:1248–54. doi:10.1161/hc3601.095927.PubMedCrossRef

59.

Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–8. doi:10.1161/01.CIR.0000091405.00772.6E.PubMedCrossRef

60.

Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005;23:2063–70.PubMed

61.

Solomon S, Appelbaum E, Manning W, et al. Effect of the direct renin inhibitor aliskiren either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy (ALLAY) trial [late breaker presentation]. Presented at: American College of Cardiology Scientific Sessions; March 29–April 1, 2008; Chicago, IL.

62.

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1–266.

63.

So WY, Kong AP, Ma RC, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006;29:2046–52. doi:10.2337/dc06-0248.PubMedCrossRef

64.

Cirillo M, Lanti MP, Menotti A, et al. Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med. 2008;168:617–24. doi:10.1001/archinte.168.6.617.PubMedCrossRef

65.

Marshall SM. Screening for microalbuminuria: which measurement? Diabet Med. 1991;8:706–11.PubMedCrossRef

66.

Jensen JS, Clausen P, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant. 1997;12:6–9. doi:10.1093/ndt/12.1.6.PubMedCrossRef

67.

Chiarelli F, Verrotti A, Mohn A, Morgese G. The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: therapeutic implications. Ann Med. 1997;29:439–45. doi:10.3109/07853899708999374.PubMedCrossRef

68.

de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl. 2004;66:S2–6. doi:10.1111/j.1523-1755.2004.09201.x.CrossRef

69.

Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198–202. doi:10.1161/01.HYP.0000154082.72286.2a.PubMedCrossRef

70.

Servais A, Giral P, Bernard M, et al. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121:426–32. doi:10.1016/j.amjmed.2008.01.040.PubMedCrossRef

71.

Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Pawlak K, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrol Carlton. 2008;13:153–6. doi:10.1111/j.1440-1797.2007.00899.x.CrossRef

72.

Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–4. doi:10.1136/bmj.321.7274.1440.PubMedCrossRef

73.

Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9. doi:10.1056/NEJMoa011161.PubMedCrossRef

74.

Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–7. doi:10.1053/j.ajkd.2004.10.019.PubMedCrossRef

75.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46. doi:10.1056/NEJMoa0708379.PubMedCrossRef

Title: Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension
Author: Alan S. Maisel
Publication date: 01-08-2009
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 4/2009
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-009-6177-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension

Abstract

Introduction

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2009

One Hour Reperfusion is Enough to Assess Function and Infarct Size With TTC Staining in Langendorff Rat Model

Statins and Vitamin D

Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D After Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?

The President’s Page: Target Response or Target Dose

Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article “The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy”

Treatment of Hypertension in Metabolic Syndrome Subjects with Amlodipine and Olmesartan—Effects on Oxidized Non-Esterified Free Fatty Acids and Cytokine Production

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page